| Name | Title | Contact Details |
|---|
Toronto-based digital health firm BlueDot, has developed a first-of-its-kind, global early warning technology for infectious diseases. Using artificial and human intelligence, BlueDot`s outbreak risk platform tracks over 150 infectious diseases globally in 65 languages, around the clock and anticipates their spread and impact. They empower national and international health agencies, hospitals, and businesses to better anticipate, and respond to, emerging threats.
Stroops Fitness Ctr is a Clearfield, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Kootenai Health provides a comprehensive range of medical services to patients in north Idaho, eastern Washington, Montana and the Inland Northwest at several facility locations. The main campus at Kootenai Health is located in Coeur d`Alene, Idaho and includes a 299-bed community-owned hospital. By providing outstanding health care, Kootenai Health repeatedly earns regional and national recognition.
Foundation of New York State Nurses Inc is a Guilderland, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Versartis, Inc. (NASDAQ: VSAR) is an endocrine-focused biopharmaceutical company developing novel, long-acting medicines to transform treatment for patients with endocrine disorders. The company is led by a management team with rich experience and expertise discovering, developing and commercializing innovative therapeutics for the life sciences industry. Versartis` mission is to develop, manufacture and commercialize novel therapeutics to improve and transform treatment for patients with orphan endocrine disorders. Versartis is well-positioned to deliver a major innovation to the global growth hormone deficiency (GHD) market with the company`s most advanced clinical candidate, somavaratan. Somavaratan is a novel, long-acting form of recombinant human growth hormone that is in global late-stage clinical trials to treat GHD in children and adults. Twice-monthly somavaratan is intended to reduce the burden of daily injection therapy by requiring significantly fewer injections, potentially improving compliance/adherence and treatment outcomes.